A phase Ib study by MD Anderson researchers demonstrated that targeting angiogenesis drivers—such as delta-like ligand 4 (DLL4)—may improve responses to vascular endothelial growth factor (VEGF) inhibitors and may lead to improved outcomes in patients with platinum-resistant ovarian cancer (PROC).
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe